CAS 1342276-76-9

Formel: C17H16N4O2S

InChl: InChI=1S/C17H16N4O2S/c1-23-14-4-2-3-12(9-14)10-19-16(22)21-17-20-15(11-24-17)13-5-7-18-8-6-13/h2-9,11H,10H2,1H3,(H2,19,20,21,22)

InChI Key: BDCUKYUIVYKXCQ-UHFFFAOYSA-N

SMILES: COC1=CC=CC(=C1)CNC(=O)NC2=NC(=CS2)C3=CC=NC=C3

RKI1313

CAS: 1342276-76-9

RKI1313

Formel: C₁₇H₁₆N₄O₂S

Reinheit: ≥95%

Molekulargewicht: 340.4

Ref: 54-BUP02631

RKI1313

CAS: 1342276-76-9

RKI1313 (RKI-1313) was a selective inhibitor for ROCK-dependent signaling, cytoskeletal changes, anchorage-independent colony formation, migration, and invasion

Formel: C₁₇H₁₆N₄O₂S

Reinheit: 99.70% - ≥95%

Farbe und Form: White Solid

Molekulargewicht: 340.4

Ref: TM-T2011

RKI-1313

CAS: 1342276-76-9

Reinheit: 99%

Molekulargewicht: 340.3999939

Ref: 10-F940607

RKI-1313

CAS: 1342276-76-9

RKI-1313 is an analog of RKI-1447 that is more potent as an inhibitor of ROCK1 and ROCK2. ROCK1 and ROCK2 are kinases that are involved in the regulation of cell motility, migration, and invasion. RKI-1313 has been shown to inhibit the formation of lamellipodia in cancer cells, which are actin-rich protrusions from the cell membrane that play a role in cancer progression. This drug also inhibits tumor growth in mice by blocking metastasis, or the spread of cancer cells to other parts of the body. The mechanism for this inhibition appears to be due to its ability to block ATP binding sites on ROCK1 and ROCK2.

Formel: C₁₇H₁₆N₄O₂S

Reinheit: Min. 95%

Molekulargewicht: 340.4 g/mol

Ref: 3D-SDC27676

1-(3-Methoxybenzyl)-3-(4-(pyridin-4-yl)thiazol-2-yl)urea

CAS: 1342276-76-9

Formel: C₁₇H₁₆N₄O₂S

Reinheit: 99%

Farbe und Form: Solid

Molekulargewicht: 340.3995

Ref: IN-DA009W9U